Ongoing phase I/II clinical trials are currently testing molecularly engineered IL-2 with an increased half-life in patients with steroid-refractory chronic GVHD (NCT03422627) or systemic lupus erythematosus (NCT04680637 and NCT04433585). The gene discussed is IL2; the disease is chronic graft versus host disease.